Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-La Roche Ag

Klaus Hallermayer

Anneliese Borgya

Michael Grol

Volker Klemt

Andreas Gallusser

Christoph Seidel

Juergen Spinke

Alfons Nichtl

Siegfried Looser

Hugo Katus

Leopold Von Proff

Monika Soukupova

Ulrike Kurtkaya

Sonja Fiesel

Marion Herrmann

Christina Porzig

Stefanie Kern

The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.

Antibodies recognizing genetic variants of NT-proBNP

The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. The epitopes recognized by the antibodies can slightly overlap.

Analytical sandwich test for determining NT-proBNP

The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.

Method of detecting a subfraction of proBNP

The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. One of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 38 to 50. In addition, one of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 1 to 37 or 43 to 76. The epitope recognized by the antibodies can slightly overlap.

Method of detecting native proBNP

An immunoassay for the determination of myocardial necroses using antibodies to troponin T and a binding partner B for troponin T or for the an antibody, whereby either the antibody or the binding partner B is labelled with a determinable group. The immunological complex formed which contains the determinable group is isolated by separation of the phases and the determinable group is determined in one of the phases. Furthermore, monoclonal and polyclonal antibodies to troponin T are described with a cross-reactivity of less than 5% to skeletal muscle troponin T and less than 2% to troponin I and other myofibrillar proteins.

Specific antibodies to troponin T, their production and use in a reagent for the determination of myocardial necrosis

Monoclonal antibodies to troponin T and their production

Growing community of inventors

Feldafing, Germany

Klaus Hallermayer